1. Scrip
  2. >>Business
  3. >>Deals

Dyno Therapeutics Emerges With Novartis, Sarepta Deals For Novel AAV Capsids

 
• By Mandy Jackson

Dyno raised $9m in 2018 but came out of stealth mode with deals worth up to $2bn based on its platform using high throughput biology, AI and machine learning to engineer next-generation AAV capsids.

Adeno-associated virus serotype 1. Virus is used as a vector for gene therapy
Dyno's novel AAV capsids could expand gene therapy's reach • Source: Shutterstock

The idea for Dyno Therapeutics Inc.’s CapsidMap platform for developing novel capsids for adeno-associated virus (AAV) vectors came to fruition after CEO and co-founder Eric Kelsic joined the Harvard University lab of George Church as a post-doc in 2015. The company officially launched in 2018 with $9m in seed funding and now it is emerging from stealth mode with gene therapy partnerships that Dyno says are worth up to $2bn in upfront payments, research funding and milestone fees.

Those collaborations announced on 11 May give Novartis AG and Sarepta Therapeutics Inc. access to CapsidMap, which combines high throughput biology with artificial intelligence (AI) and machine learning to identify next-generation AAV vectors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

More from Business

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.